Tags : Waldenstrom Macroglobulinemia

Pharma Regulatory

Janssen’s Imbruvica (ibrutinib) Receives CHMP Positive Recommendation for its Expanded

Shots: The CHMP’s positive opinion for CLL is based on P-III iLLUMINATE (PCYC1130) study assessing Imbruvica + obinutuzumab vs chlorambucil + obinutuzumab in patients with newly diagnosed CLL, resulted in longer m-PFS The CHMP’s positive opinion for WM is based on P-III iNNOVATE (PCYC-1127) study evaluating the ibrutinib & rituximab vs rituximab + PBO in […]Read More